Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIB | P23284 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31070317 | 1.00 | PPIB (0.52) | PPIBCYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL1818976 | 1.00 | PPIB (0.52) | PPIBCYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL1820365 | 1.00 | PPIB (0.52) | PPIBCYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL25927732 | 0.87 | PPIB (0.56) | PPIBCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL7370305 | 0.86 | PPIB (0.53) | PPIBCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1502013 | 0.86 | CYP1A2 (0.45) | PPIBCYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL23807797 | 0.86 | LMNA (0.45) | PPIBBRD4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29692669 | 0.86 | LMNA (0.45) | PPIBBRD4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10305118 | 0.85 | EPHA2 (0.42) | PPIBSMN1; SMN2USP30EPHA2USP2 | |
| SCHEMBL31314330 | 0.85 | EPHA2 (0.42) | PPIBSMN1; SMN2USP30EPHA2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023151658-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF P2X3 RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151660-A1 | CRYSTALLINE FORM OF P2X3 RECEPTOR ANTAGONIST, AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-08-17 | — | — | WO | disclosed |
| CN-102741245-B | Benzoimidazole compounds and uses thereof | ASTRAZENECA AB | 2014-11-05 | — | — | CN | disclosed |
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2501697-B1 | BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF | NEOMED INST (CA) | 2013-10-23 | — | — | EP | disclosed |
| US-8530467-B2 | Benzoimidazole compounds and uses thereof | NEOMED INSTITUTE (CA) | 2013-09-10 | — | — | US | disclosed |
| WO-2012158117-A1 | COMBINATION THERAPIES FOR TREATING PAIN | ASTRAZENECA AB (SE) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289504-A1 | Benzoimidazole Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| CN-102741245-A | Benzoimidazole compounds and uses thereof | ASTRAZENECA AB | 2012-10-17 | — | — | CN | disclosed |
| EP-2501697-A1 | BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| WO-2009104729-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 大日本住友製薬株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289504-A1 | Benzoimidazole Compounds and Uses Thereof | TPMT, BRD4, CYP3A4 | PPIB 2026/4885CYP1A2 95/4885CYP2C9 36/4885 |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | PPIB 4728/4885CYP1A2 1665/4885CYP2C9 2748/4885 |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | PPIB 2843/4885CYP1A2 446/4885CYP2C9 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.